| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 139 |
| 1 | TACROLIMUS | 85 |
| 2 | CYCLOPHOSPHAMIDE | 84 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 84 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 84 |
| 5 | METHOTREXATE SODIUM | 78 |
| 6 | PREDNISONE | 75 |
| 7 | INFLIXIMAB | 73 |
| 8 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 72 |
| 9 | TACROLIMUS OINTMENT 0.1% | 72 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PAROMOMYCIN SULFATE | 4 | 0.0377 |
| 1 | ALUMINUM SULFATE TETRADECAHYDRATE, CALCIUM ACETATE MONOHYDRATE | 1 | 0.0169 |
| 2 | LEVOBUNOLOL HYDROCHLORIDE | 1 | 0.0099 |
| 3 | DAUNORUBICIN HYDROCHLORIDE | 10 | 0.0061 |
| 4 | SACROSIDASE | 1 | 0.0055 |
| 5 | METEX | 2 | 0.0053 |
| 6 | HALOBETASOL PROPIONATE AND TAZAROTENE | 1 | 0.0051 |
| 7 | CLOMIPRAMINE HYDROCHLORIDE | 20 | 0.0044 |
| 8 | TRIMIPRAMINE | 4 | 0.0036 |
| 9 | INFLIXIMAB-DYYB | 12 | 0.0035 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 167 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 123 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 98 |
| 3 | Alkylating Drug [EPC] | 96 |
| 4 | Proton Pump Inhibitor [EPC] | 82 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 74 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 74 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 67 |
| 8 | Kinase Inhibitor [EPC] | 65 |
| 9 | Benzodiazepine [EPC] | 64 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 6 | 0.0087 |
| 1 | Sucrose-specific Enzyme [EPC] | 1 | 0.0055 |
| 2 | Polyene Antimicrobial [EPC] | 1 | 0.0024 |
| 3 | Selective T Cell Costimulation Blocker [EPC] | 9 | 0.0019 |
| 4 | 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC] | 1 | 0.0012 |
| 5 | Guanylate Cyclase-C Agonist [EPC] | 2 | 0.0010 |
| 6 | Provitamin D2 Compound [EPC] | 23 | 0.0008 |
| 7 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 2 | 0.0006 |
| 8 | BCL-2 Inhibitor [EPC] | 37 | 0.0006 |
| 9 | Purine Antimetabolite [EPC] | 58 | 0.0006 |